The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
Open accessAbstract
Inhibitory molecules of the B7/CD28 family play a key role in the induction of immune tolerance in the tumor microenvironment. The programmed death-1 receptor (PD-1), with its ligands PD-L1 and PD-L2, constitutes an important member of these inhibitory pathways. The relevance of the PD-1/PD-L1 pathway in cancer has been extensively studied and therapeutic approaches targeting PD-1 and PD-L1 have been developed and are undergoing human clinical testing. However, PD-L2 has not received as much attention and its role in modulating tumor immunity is less clear. Here, we review the literature on the immunobiology of PD-L2, particularly on its possible roles in cancer-induced immune suppression and we discuss the results of recent studies targeting PD-L2 in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
Tissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,211
Expression of Programmed Death 1 Ligands by Murine T Cells and APC
Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5538 · Cited by 951
Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889
Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
Gao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778 · cited 1×
“The net result of these PD-1-induced cascades is an impairment of proliferation, cytokine production, cytolytic function, and survival of the T cell [42].”
BackgroundDe Monte, L., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H., Braga, M., Di Carlo, V., Doglioni, C., & Protti, M. P. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101876 · Cited by 695
Immunotherapy and chemotherapy — a practical partnership
Lake, R. A., & Robinson, B. W. S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1613 · Cited by 646
Self-citationRegulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses
Liang, S. C., Latchman, Y. E., Buhlmann, J. E., Tomczak, M. F., Horwitz, B. H., Freeman, G. J., & Sharpe, A. H. (2003) · European Journal of Immunology · doi:10.1002/eji.200324228 · Cited by 639
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
Loke, P., & Allison, J. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931259100 · Cited by 634
Liu, J., Hamrouni, A., Wolowiec, D., Coiteux, V., Kuliczkowski, K., Hetuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580
Das, J., Chen, C.-H., Yang, L., Cohn, L., Ray, P., & Ray, A. (2001) · Nature Immunology · doi:10.1038/83158 · Cited by 518
Kinter, A. L., Godbout, E. J., McNally, J. P., Sereti, I., Roby, G. A., O’Shea, M. A., & Fauci, A. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6738 · Cited by 513
Salama, A. D., Chitnis, T., Imitola, J., Ansari, M. J. I., Akiba, H., Tushima, F., Azuma, M., Yagita, H., Sayegh, M. H., & Khoury, S. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022119 · Cited by 506
Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis
Rodig, N., Ryan, T., Allen, J. A., Pang, H., Grabie, N., Chernova, T., Greenfield, E. A., Liang, S. C., Sharpe, A. H., Lichtman, A. H., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324270 · Cited by 492
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
Lin, D. Y.-W., Tanaka, Y., Iwasaki, M., Gittis, A. G., Su, H.-P., Mikami, B., Okazaki, T., Honjo, T., Minato, N., & Garboczi, D. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712278105 · Cited by 457
Chen, F., Liu, Z., Wu, W., Rozo, C., Bowdridge, S., Millman, A., Van Rooijen, N., Urban, J. F., Wynn, T. A., & Gause, W. C. (2012) · Nature Medicine · doi:10.1038/nm.2628 · Cited by 449
Cancer immunotherapy – revisited
Lesterhuis, W. J., Haanen, J. B. A. G., & Punt, C. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3500 · Cited by 427
Self-citationPD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Zhang, L., Gajewski, T. F., & Kline, J. (2009) · Blood · doi:10.1182/blood-2009-03-206672 · Cited by 411
Mühlbauer, M., Fleck, M., Schütz, C., Weiss, T., Froh, M., Blank, C., Schölmerich, J., & Hellerbrand, C. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.007 · Cited by 378
Activation of STAT6 by STING Is Critical for Antiviral Innate Immunity
Chen, H., Sun, H., You, F., Sun, W., Zhou, X., Chen, L., Yang, J., Wang, Y., Tang, H., Guan, Y., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.022 · Cited by 372
The role of the PD‐1 pathway in autoimmunity and peripheral tolerance
Fife, B. T., & Pauken, K. E. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05919.x · Cited by 355
Tissue-based class control: the other side of tolerance
Matzinger, P., & Kamala, T. (2011) · Nature Reviews Immunology · doi:10.1038/nri2940 · Cited by 343
Lesterhuis, W. J., Punt, C. J. A., Hato, S. V., Eleveld-Trancikova, D., Jansen, B. J. H., Nierkens, S., Schreibelt, G., de Boer, A., Van Herpen, C. M. L., Kaanders, J. H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43656 · Cited by 340
Self-citationAspord, C., Pedroza-Gonzalez, A., Gallegos, M., Tindle, S., Burton, E. C., Su, D., Marches, F., Banchereau, J., & Palucka, A. K. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061120 · Cited by 334
Signaling mechanisms, interaction partners, and target genes of STAT6
HEBENSTREIT, D., WIRNSBERGER, G., HOREJSHOECK, J., & DUSCHL, A. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.01.004 · Cited by 308
Wang, S., Bajorath, J., Flies, D. B., Dong, H., Honjo, T., & Chen, L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021752 · Cited by 291
Nazareth, M. R., Broderick, L., Simpson-Abelson, M. R., Kelleher, R. J., Yokota, S. J., & Bankert, R. B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.9.5552 · Cited by 259
T‐cell tolerance or function is determined by combinatorial costimulatory signals
Nurieva, R., Thomas, S., Nguyen, T., Martin‐Orozco, N., Wang, Y., Kaja, M., Yu, X., & Dong, C. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601146 · Cited by 245
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation
Pedroza-Gonzalez, A., Xu, K., Wu, T.-C., Aspord, C., Tindle, S., Marches, F., Gallegos, M., Burton, E. C., Savino, D., Hori, T., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102131 · Cited by 237
PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
Ghiotto, M., Gauthier, L., Serriari, N., Pastor, S., Truneh, A., Nunes, J. A., & Olive, D. (2010) · International Immunology · doi:10.1093/intimm/dxq049 · Cited by 229
Differential binding properties of B7-H1 and B7-DC to programmed death-1
Youngnak, P., Kozono, Y., Kozono, H., Iwai, H., Otsuki, N., Jin, H., Omura, K., Yagita, H., Pardoll, D. M., Chen, L., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01257-9 · Cited by 209
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
Lázár-Molnár, E., Yan, Q., Cao, E., Ramagopal, U., Nathenson, S. G., & Almo, S. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804453105 · Cited by 206
Huber, S., Hoffmann, R., Muskens, F., & Voehringer, D. (2010) · Blood · doi:10.1182/blood-2010-02-271981 · Cited by 204
Parekh, V. V., Lalani, S., Kim, S., Halder, R., Azuma, M., Yagita, H., Kumar, V., Wu, L., & Van Kaer, L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803648 · Cited by 197
Zhong, X., Tumang, J. R., Gao, W., Bai, C., & Rothstein, T. L. (2007) · European Journal of Immunology · doi:10.1002/eji.200737461 · Cited by 190
PD-1 Ligand Expression by Human Colonic Myofibroblasts/Fibroblasts Regulates CD4+ T-Cell Activity
Pinchuk, I. V., Saada, J. I., Beswick, E. J., Boya, G., Qiu, S. M., Mifflin, R. C., Raju, G. S., Reyes, V. E., & Powell, D. W. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.016 · Cited by 184
Akbari, O., Stock, P., Singh, A. K., Lombardi, V, Lee, W.-L., Freeman, G. J., Sharpe, A. H., Umetsu, D. T., & DeKruyff, R. H. (2010) · Mucosal Immunology · doi:10.1038/mi.2009.112 · Cited by 182
Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation
Kanai, T., Totsuka, T., Uraushihara, K., Makita, S., Nakamura, T., Koganei, K., Fukushima, T., Akiba, H., Yagita, H., Okumura, K., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.4156 · Cited by 170
Regulation of T cell activation and tolerance by PDL2
Zhang, Y., Chung, Y., Bishop, C., Daugherty, B., Chute, H., Holst, P., Kurahara, C., Lott, F., Sun, N., Welcher, A. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601347103 · Cited by 159
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses
Shin, T., Yoshimura, K., Shin, T., Crafton, E. B., Tsuchiya, H., Housseau, F., Koseki, H., Schulick, R. D., Chen, L., & Pardoll, D. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050072 · Cited by 159
Yin–Yang of costimulation: crucial controls of immune tolerance and function
Nurieva, R. I., Liu, X., & Dong, C. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00769.x · Cited by 157
Hobo, W. A., Maas, F., Adisty, N., de Witte, T., Schaap, N. P., van der Voort, R., & Dolstra, H. (2010) · Blood · doi:10.1182/blood-2010-04-278739 · Cited by 154
Pilon‐Thomas, S., Mackay, A., Vohra, N. A., & Mulé, J. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904114 · Cited by 150
B7-DC Regulates Asthmatic Response by an IFN-γ-Dependent Mechanism
Matsumoto, K., Inoue, H., Nakano, T., Tsuda, M., Yoshiura, Y., Fukuyama, S., Tsushima, F., Hoshino, T., Aizawa, H., Akiba, H., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2530 · Cited by 146
Diegelmann, J., Olszak, T., Göke, B., Blumberg, R. S., & Brand, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.294355 · Cited by 132
He, Y., Zhang, G., Wang, X., Zhang, H., Yuan, Y., Li, D., & Feng, Z. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4919 · Cited by 126
PD-L2 is expressed on activated human T cells and regulates their function
Messal, N., Serriari, N., Pastor, S., Nunès, J. A., & Olive, D. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.06.436 · Cited by 122
Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model
Miura, M. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000387 · Cited by 120
Zhu, B., Guleria, I., Khosroshahi, A., Chitnis, T., Imitola, J., Azuma, M., Yagita∥, H., Sayegh, M. H., & Khoury, S. J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3480 · Cited by 114
Stanciu, L. A., Bellettato, C. M., Laza‐Stanca, V., Coyle, A. J., Papi, A. A., & Johnston, S. L. (2006) · The Journal of Infectious Diseases · doi:10.1086/499275 · Cited by 99
siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions
Iwamura, K., Kato, T., Miyahara, Y., Naota, H., Mineno, J., Ikeda, H., & Shiku, H. (2011) · Gene Therapy · doi:10.1038/gt.2011.185 · Cited by 62
Grabmeier‐Pfistershammer, K., Klauser, C., Pickl, W. F., Stöckl, J., Leitner, J. M., Zlabinger, G. J., Majdic, O., & Steinberger, P. (2006) · European Journal of Immunology · doi:10.1002/eji.200535344 · Cited by 50
PD-L2 is predominantly expressed by Th2 cells
Lesterhuis, W. J., Steer, H. J., & Lake, R. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.09.014 · Cited by 47
Self-citationCostimulator B7-DC Attenuates Strong Th2 Responses Induced by Nippostrongylus brasiliensis
Ishiwata, K., Watanabe, N., Guo, M., Tomihara, K., Brumlik, M. J., Yagita∥, H., Pardoll, D. M., Chen, L., & Shin, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0804051 · Cited by 44
STATing the importance of immune modulation by platinum chemotherapeutics
Hato, S. V., de Vries, I. J. M., & Lesterhuis, W. J. (2012) · OncoImmunology · doi:10.4161/onci.1.2.18126 · Cited by 34
Self-citationIL-4-stimulated NF-κB activity is required for Stat6 DNA binding
Thieu, V. T., Nguyen, E., McCarthy, B. P., Bruns, H. A., Kapur, R., Chang, C., & Kaplan, M. H. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1106707 · Cited by 31
Gorski, K. S. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(03)00085-3 · Cited by 14
Cited by
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
“PD-L2 is primarily expressed on dendritic cells and monocytes, but can be induced on a wide variety of other immune cells and nonimmune cells, depending on the local microenvironment.(29) PD-1 has a higher binding affinity for PDL2 than for PD-L1, and this difference may be responsible for differential contributions o…”
BackgroundClassifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,411
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
Nguyen, L. T., & Ohashi, P. S. (2015) · Nature Reviews Immunology · doi:10.1038/nri3790 · Cited by 627
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Yearley, J. H., Gibson, C., Yu, N., Moon, C., Murphy, E., Juco, J., Lunceford, J., Cheng, J., Chow, L. Q. M., Seiwert, T. Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1761 · Cited by 594
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Metadata
- Authors
- Rozali, E. N., Hato, S. V., Robinson, B. W., Lake, R. A., & Lesterhuis, W. J.
- Venue
- Clinical and Developmental Immunology
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 2012
- Pages
- 1-8
- ISSN
- 1740-2522 (ISSN-L)
- 1740-2530
- OpenAlex
- W2095692889
- Cited by
- 328
- References
- 73
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.